Difference between revisions of "European Federation of Pharmaceutical Industries and Associations"
Mira Purska (talk | contribs) |
Mira Purska (talk | contribs) |
||
| Line 1: | Line 1: | ||
EFPIA claims to represent the pharmaceutical industry operating in Europe being 'the voice on the EU scene of 2,100 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world'.<ref>http://http://www.efpia.org/Content/Default.asp</ref> It is based in Brussels and its mission is to 'to improve the competitiveness of the research-based pharmaceutical industry in Europe in a regulatory and political environment, which above all stimulates R&D and rewards innovation.'<ref>http://www.efpia.org/content/default.asp?PageID=90</ref> | EFPIA claims to represent the pharmaceutical industry operating in Europe being 'the voice on the EU scene of 2,100 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world'.<ref>http://http://www.efpia.org/Content/Default.asp</ref> It is based in Brussels and its mission is to 'to improve the competitiveness of the research-based pharmaceutical industry in Europe in a regulatory and political environment, which above all stimulates R&D and rewards innovation.'<ref>http://www.efpia.org/content/default.asp?PageID=90</ref> | ||
| − | In 2007 27 European Union member states signed the Innovative Medicines Initiative. This alliance between the European Commission and the European Federation of Pharmaceutical Industries and Associations has a budget of 2.0 billion euros ($2.94 billion) over a seven-year period aimed at 'giving a boost to the EU's competitiveness in biomedical innovation'<ref>[IMI to be adopted by 27 EU states]Pharma Marketletter, December 14, 2007 </ref> | + | In 2007 27 European Union member states signed the Innovative Medicines Initiative. This alliance between the European Commission and the European Federation of Pharmaceutical Industries and Associations has a budget of 2.0 billion euros ($2.94 billion) over a seven-year period aimed at 'giving a boost to the EU's competitiveness in biomedical innovation'<ref> [IMI to be adopted by 27 EU states] Pharma Marketletter, December 14, 2007 </ref> |
Revision as of 16:20, 9 January 2008
EFPIA claims to represent the pharmaceutical industry operating in Europe being 'the voice on the EU scene of 2,100 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world'.[1] It is based in Brussels and its mission is to 'to improve the competitiveness of the research-based pharmaceutical industry in Europe in a regulatory and political environment, which above all stimulates R&D and rewards innovation.'[2]
In 2007 27 European Union member states signed the Innovative Medicines Initiative. This alliance between the European Commission and the European Federation of Pharmaceutical Industries and Associations has a budget of 2.0 billion euros ($2.94 billion) over a seven-year period aimed at 'giving a boost to the EU's competitiveness in biomedical innovation'[3]
Membership
Fachverband der Chemischen Industrie Österreichs (Austria)
Association Générale de l’Industrie du Médicament (Belgium)
Laegemiddelindustriforeningen the Danish Association of the Pharmaceutical Industry (Denmark)
Lääketeollisuus ry Pharma Industry (Finland)
Les Entreprises du Médicament (France)
Verband Forschender Arzneimittelhersteller (Germany)
Hellenic Association of Pharmaceutical Companies (Greece)
Irish Pharmaceutical Healthcare Association (Ireland)
Associazione delle imprese del farmaco (Italy)
Vereniging Innovatieve Geneesmiddelen Nederland (Netherlands)
Legemiddelindustriforeningen Norwegian Association of Pharmaceutical Manufacturers (Norway)
Employers Union of Innovative Pharmaceutical Companies (Poland)
Associação Portuguesa da Indústria Farmacêutica (Portugal)
Asociación Nacional Empresarial de la Industria Farmacéutica (Spain)
Läkemedelsindustriföreningen The Swedish Association of the Pharmaceutical Industry (Sweden)
Société Suisse des Industries Chimiques (Switzerland)
Arastirmaci Ilac Firmalari Dernegi (Turkey)
The Association of the British Pharmaceutical Industry (UK)
Bundesverband der Pharmazeutischen Industrie (Founder Member)
People
- Arthur Higgins President
- Tom McKiIIop
- Brian Ager Director General
- Marie-Claire Pickaert Deputy Director General
- Andreas Preising Manager, Government Affairs
- Chantal Porges Director, Communication & Partnerships
- Magdalena Rodriguez de Azero Executive Manager, European Vaccine Manufacturers (EVM)
- Emmanuel Chantelot Executive Manager, European Biopharmaceutical Enterprises (EBE)
- Christine-Lise Julou Manager, Scientific, Technical & Regulatory Affairs
- Karen Strandgaard Manager, Research Directors Group
- Louis-Nicolas Fortin Manager, External Trade
- Brendan Barnes Manager, Multilateral Affairs
- Magda Chlebus Manager, CEE Region Affairs
- Ann Robins Manager, Legal Affairs
- Christine-Lise Julou Manager, Scientific, Technical & Regulatory Affairs
References
- ↑ http://http://www.efpia.org/Content/Default.asp
- ↑ http://www.efpia.org/content/default.asp?PageID=90
- ↑ [IMI to be adopted by 27 EU states] Pharma Marketletter, December 14, 2007
